Opinion

Video

ASH 2024 Highlights: Phase 2 Study of Zanubrutinib Plus Venetoclax in R/R CLL

Panelists discuss how the phase 2 study of zanubrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia (R/R CLL) demonstrated promising efficacy with deep and durable responses, suggesting this combination could be an effective option for previously treated patients while maintaining a manageable safety profile.

Video content above is prompted by the following:

  • One ASH abstract I wanted to highlight was a phase 2 study of zanubrutinib and venetoclax in the R/R setting. Please share key findings and your impressions.
Related Videos
5 experts are featured in this series
5 experts are featured in this series
4 experts are featured in this series.
2 expert is featured in this series.
4 experts are featured in this series.